Symbiotix Biotherapies Overview

  • Founded
  • 2009


  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Symbiotix Biotherapies General Information


Developer of a novel class of molecular therapeutics intended to treat inflammatory bowel disease. The company's novel class of molecular therapeutics are oral agents based on molecules derived from the human microbiom which are used for multiple sclerosis and other serious immune-mediated diseases, enabling patients to improve their lives and treat inflammatory disaeses.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • One International Place
  • Suite 1400
  • Boston, MA 02110
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Symbiotix Biotherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Oct-2019 000 Completed Out of Business
5. Later Stage VC (Series A) 01-Nov-2017 000 000 0000 Completed Generating Revenue
4. Grant 21-Sep-2016 000 Completed Startup
3. Later Stage VC Completed Startup
2. Grant 01-Jun-2015 $2.98M Completed Startup
1. Grant 15-Jul-2014 $720K Completed Startup
To view Symbiotix Biotherapies’s complete valuation and funding history, request access »

Symbiotix Biotherapies Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 00,000 00.000000 000.00 000.00 00 000.00 0.000
Series A2 000,000 00.000000 000.0 000.0 00 000.0 0.000
Series A1 303,796 $0.001000 $7.9 $7.9 1x $7.9 10.88%
To view Symbiotix Biotherapies’s complete cap table history, request access »